October 2025 in “Actas Dermo-Sifiliográficas” RF-mesotherapy with bicalutamide may be a promising new treatment for hair loss.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for treating prostate issues and hair loss without hormonal side effects.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for hair loss and prostate issues without hormonal side effects.
Bicalutamide does not significantly affect liver enzymes and is a safe anti-androgen option for transfeminine individuals.
42 citations
,
April 2011 in “Annals of Pharmacotherapy” Flutamide effectively treats female pattern hair loss with low doses showing good liver tolerance.
June 2023 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” Bicalutamide mesotherapy improved hair density in women with hair loss and was well received.
72 citations
,
June 1979 in “Biochemical Society Transactions” Flutamide and its metabolite can effectively reduce androgen effects.
19 citations
,
December 2021 in “Cureus” Proxalutamide improved recovery, lowered death rates, and reduced hospital stay for COVID-19 patients.
November 2005 in “The Journal of Urology”
30 citations
,
March 2011 in “Australasian Journal of Dermatology” Flutamide improves female hair loss when other treatments fail, but may cause liver toxicity.
29 citations
,
July 2012 in “Fertility and Sterility” Low and ultralow doses of flutamide can cause liver damage in young women with high androgen levels, regardless of dose or birth control use, with higher risk for those with higher BMI and liver enzyme levels before treatment.
Flutamide effectively treats female pattern hair loss long-term with low doses being safe for the liver.
November 1990 in “Inpharma weekly” Flutamide effectively treated hair growth and related symptoms in women, with common side effects like dry skin and hot flushes.
27 citations
,
October 1991 in “International journal of gynaecology and obstetrics” Flutamide effectively reduces hair growth in women with hirsutism and improves acne and seborrhea without side effects.
August 2025 in “JAAD International” Bicalutamide may take longer to work for female hair loss, and higher doses might be needed.
December 2013 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” Flutamide, an oral anti-androgen therapy, is effective in treating female pattern hair loss, even without systemic androgen excess.
May 2025 in “Journal of the American Academy of Dermatology” Bicalutamide shows promise for treating female hair loss.
49 citations
,
January 1994 in “The Journal of Steroid Biochemistry and Molecular Biology” RU 58841 may treat acne, hair loss, and excessive hair growth.
23 citations
,
October 2008 in “Journal of medicinal chemistry” PF-998425 is a new, effective, and non-phototoxic treatment for skin conditions related to androgens.
8 citations
,
January 1987 in “Gynecological Endocrinology” Flutamide, an antiandrogen, has minimal impact on female rat endocrine systems and does not significantly change their reproductive cycles.
9 citations
,
March 1991 in “Endocrinology” Using two drugs together, Flutamide and 4-MA, is more effective for blocking male hormones than using each one alone.
42 citations
,
February 1998 in “The Journal of Steroid Biochemistry and Molecular Biology” PNU 157706 is a more effective treatment than finasteride for conditions caused by DHT, like enlarged prostate and hair loss.
Cyproterone acetate is used for topical treatment of diseases dependent on male hormones.
1 citations
,
June 2007 in “Journal of Clinical Oncology” Weekly bicalutamide is safe and effective, with 50 mg/week recommended.
1 citations
,
March 2022 in “Journal of The American Academy of Dermatology” Adjusting minoxidil dosage may be safer than using bicalutamide for hair loss in women.
December 2005 in “Endocrine-related cancer” A woman's adrenal tumor disappeared after treatment with cyproterone acetate.
September 2021 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature”
18 citations
,
January 1998 in “Endocrine” RU58841, a nonsteroidal anti-androgen, showed potential as a topical treatment for hair loss, increasing hair density, thickness, and length without systemic side effects in Stumptailed Macaques.
52 citations
,
July 1998 in “Urology” Liarozole may be more effective than cyproterone acetate for treating advanced prostate cancer, with better PSA response and survival rates, while maintaining quality of life.
1 citations
,
January 1995 in “Journal of Investigative Dermatology” RU58841, a substance from France, can potentially block the effects of hormones that cause hair loss and excessive hair growth, performing better than a similar substance, cyproterone acetate.